This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognizing you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful. Check our privacy policy here.
Funding
NUEVO INHIBIDOR DE JAK RESTRINGIDO AL INTESTINO PARA SUPERAR LA TOXICIDAD SISTÉMICA EN EL
TRATAMIENTO DE LA ENFERMEDAD INFLAMATORIA INTESTINAL
Código: SoE-20251013
Objetivo: El proyecto tiene como objetivo avanzar el desarrollo clínico de OST-122, el primer inhibidor de JAK restringido al tracto gastrointestinal (GI) para el tratamiento local y seguro de la Enfermedad Inflamatoria Intestinal (EII), evitando toxicidades sistémicas. Se prevé como una solución transformadora frente a los tratamientos actuales, con resultados prometedores en fases preclínicas y clínicas (fases 1 y 2a), y una próxima fase 2b en pacientes con colitis ulcerosa (CU) en preparación
Presupuesto total: 3.413.665,00€
Subvención: 2.389.565,50 €
Duración: 01/07/2025 – 31/12/2026
NEW INTESTINE-RESTRICTED JAK INHIBITOR TO OVERCOME SYSTEMIC TOXICITY IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE
Code: SoE-20251013
Objective: The project aims to advance the clinical development of OST-122, the first JAK inhibitor restricted to the gastrointestinal (GI) tract for the local and safe treatment of Inflammatory Bowel Disease (IBD), avoiding systemic toxicities. It is envisaged as a transformative solution compared with current treatments, with promising results in preclinical and clinical phases (phases 1 and 2a), and a forthcoming phase 2b in patients with ulcerative colitis (UC) in preparation.
Total budget: €3,413,665.00
Grant: €2,389,565.50
Duration: 01/07/2025 – 31/12/2026
Oncostellae is owned primarily by the founders and the institutional investors Inveready, Xesgalicia, Fitalent, Unirisco and Bio&Tech Smart Capital
Public funding
Oncostellae has received the Seal of Excellence from the European Commission for its project proposal 101188186 — JAKi-IBD: “Novel gut-restricted JAK inhibitor to overcome systemic toxicity in the treatment of inflammatory bowel disease” submitted under the Horizon Europe EIC Accelerator call 2024.
Oncostellae is part of the Public-Private Partnership project CPP2023-010778 funded by the Ministerio de Ciencia, Innovación y Universidades /Agencia Estatal de Investigación /10.13039/501100011033/ FEDER and European Regional Development Fund.
Oncostellae has received funding through the program Conecta Pyme cofinanced by the Agencia Gallega de Innovación (GAIN) and the European Regional Development Fund (ERDF) and supported by the Consellería de Economía, Empleo e Industria (Xunta de Galicia) to execute the following projects:
“ONCOGALFARMA – Development of novel complementing therapies for the treatment of oncological diseases.” (IN852A 2014/1)
“NEOGALFARM – New anti-cancer drugs: Development of therapies directed at multiple therapeutic targets and combination treatments” (IN852A 2016/2)
“IO4COLON – Industrial research toward the discovery of novel immunotherapeutics for the treatment of colon cancer” (IN852A 2018/3)
Oncostellae has received funding through the program Conecta Pyme cofinanced by the Agencia Gallega de Innovación (GAIN) and the European Regional Development Fund (ERDF) and supported by the Consellería de Economía, Empleo e Industria (Xunta de Galicia) to execute the following projects:
“ONCOGALFARMA – Development of novel complementing therapies for the treatment of oncological diseases.” (IN852A 2014/1)
“NEOGALFARM – New anti-cancer drugs: Development of therapies directed at multiple therapeutic targets and combination treatments” (IN852A 2016/2)
“IO4COLON – Industrial research toward the discovery of novel immunotherapeutics for the treatment of colon cancer” (IN852A 2018/3)
INHIBIDORES NO-SISTEMICOS JAK PARA TRATAMIENTOS MÁS SEGUROS EN CU Y EC
«Proyecto CPP2021-009055, financiado por MCIN/AEI/10.13039/501100011033 y por la Unión Europea-NextGenerationEU/PRTR»
Entidades participantes: ONCOSTELLAE, S.L. y FUNDACION INSTITUTO DEINVESTIGACIÓN SANITARIA DE SANTIAGO
Período:01/02/2022 – 31/12/2025
Oncostellae has been a beneficiary, within the framework of the Recovery, Transformation and Resilience Plan and the State Program to Catalyze Innovation and Business Leadership of the State Plan for Scientific, Technical and Innovation Research 2021-2023, of the grant for the»Science and Innovation Missions Program» (EXP 00146129 / MIP-20211011)
Title: RESEARCH AND DEVELOPMENT OF THREE NEW THERAPIES DIRECTED FOR THE PERSONALIZED TREATMENT OF CANCER
«Subsidised by the CDTI and supported by the Ministerio de Ciencia e Innovación».
Oncostellae has got access to ERDF funds through the support from the Ministerio de Ciencia, Innovación y Universidades within the program “Retos” to execute the following project:
“Retos Colaboración – Research and Phase I development of novel kinase inhibitors for the treatment of diseases along the inflammation-fibrosis-cancer axis.” (RTC-2017-6403-1)
Oncostellae has received the following parcipative loans from the Empresa Nacional de Innovación S.A. (ENISA) supported by the Ministerio de Industria, Comercio y Turismo:
ENISA Emprendedor (2016)
ENISA Colaboración (2020)
Investors
Inveready is one of the leading early-stage venture capital companies in Spain, with five investment funds. Inveready invests in technology companies with high growth potential and innovative business models. Inveready has extensive experience in different areas, with more than 40 portfolio companies that are leaders in their respective sectors.
Fitalent (FIT Inversión en Talento SCR de Régimen Simplificado SL) es una sociedad de capital riesgo constituida a principios de 2011 e inscrita en el registro especial de la Comisión Nacional del Mercado de Valores (CNMV), que invierte en empresas de base tecnológica y con productos de éxito probado, cuyo principal activo sean las personas y el talento.
XesGalicia is a management company of venture capital firms that focuses on promoting the economic and industrial development and consolidation of businesses in Galicia, from four different investment vehicles. XesGalicia offers financing to different types of projects, from new enterprise initiatives to established industrial projects with a long history.
Unirisco is a private venture capital company promoting the creation of companies born in university, technology and R&D ecosystems that have a positive impact on the Spanish region of Galicia and on its surroundings.
Bio&Tech Smart Capital is the first Galician vertical investment fund specialized in the biotech, med tech, health tech, diagnostics and digital sectors oriented to life sciences.
This company is capitalized by INNVIERTE, AN INVESTMENT PROGRAM OF CDTI, E.P.E.
Esta empresa está capitalizada por INNVIERTE, INICIATIVA DE INVERSIÓN DE CDTI, E.P.E.
R&D Projects
Corporate Projects
Other Support Resources
Funding
Enisa
Oncostellae is supported by ENISA (a public institution that finances new and innovative program) and co-financied by the European Regional Development Fund: «A way to build Europe«.
